Compare Amgen, Inc. (AMGN) vs Core and Main Inc (CNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Core and Main Inc — how do they compare? Amgen, Inc. trades at $415.49 (market cap $224.14B), while Core and Main Inc trades at $45.92 (market cap $8.73B). The key difference: Amgen, Inc. is far larger — about 25.7× Core and Main Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| AMGN | CNM | |
|---|---|---|
Market Cap | $224.14B | $8.73B |
Sector | Health | Technology |
52-Week High | $417.20 | $66.98 |
52-Week Low | $271.18 | $42.37 |
Enterprise Value | $267.45B | $11.02B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Core & Main (CNM) trades at $45.85, down 0.97% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings of $0.57 per share, beating estimates, and maintains solid fundamentals including a 23.73% ROE and 5.87% net margin. Recent news highlights institutional activity, such as California State Teachers Retirement System increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is positive with analyst consensus at 57% buy ratings, supported by revenue growth to $7.6B in 2026 and expanding margins. Risks include high debt levels at $2.24B long-term and competitive pressures in the tools sector. Investors should monitor execution against FY26 guidance of $7.8–$7.9B revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
